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In premenopausal women, estrogen therapy has different
effects in smokers and nonsmokers. Studies of oral contra-
ceptive pills consistently find that hormone use results in a
much higher relative risk for cardiovascular events in smok-
ers than in nonsmokers. For example, in the World Health
Organization Collaborative Study of Cardiovascular Dis-
ease and Steroid Hormone Contraception, use of oral
contraceptives increased risk for myocardial infarction about
four-fold among nonsmokers, but more than 20-fold among
smokers (1).
In this issue of the Journal, Teede et al. (2) present data
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from a cross-sectional study of 140 postmenopausal women
showing better arterial structure (intimal medial thickness of
the carotid artery) and function (systemic arterial compli-
ance) among postmenopausal hormone users compared to
nonusers (2). The apparent benefit of hormone use was
observed in smokers, but not in nonsmokers. This study
suggests that, like oral contraceptive pill use, postmeno-
pausal hormone therapy affects smokers and nonsmokers
differently. However, it is unclear why smokers who use
postmenopausal estrogen might be at lower risk for coronary
disease, when smokers who use oral contraceptive estrogen
are clearly at increased risk.
Does this study suggest that we should offer postmeno-
pausal smokers hormone therapy to offset the increased risk
of coronary disease associated with smoking? It is important
to keep in mind that the study by Teede et al. (2) is an
observational study with surrogate outcomes. More than 40
other observational studies suggest a 35% to 50% reduction
in risk of coronary heart disease in women using hormone
therapy compared with nonusers (3,4). Studies of other
surrogate outcomes (lipoproteins, smooth muscle cell pro-
liferation, oxidative potential, brachial artery reactivity, cor-
onary cross-sectional area and coronary blood flow) also
suggest that postmenopausal estrogen therapy reduces risk
for coronary disease (5). Why might observational studies,
particularly those with surrogate outcomes, provide the
wrong answer?
Women who take postmenopausal hormone therapy are
healthier, wealthier and have better coronary risk profiles
than nonusers (6,7). This potential selection bias might
account for some of the lower risk of coronary events
observed in hormone users. In addition, adherence to
medications appears to be a marker for lower coronary risk.
For example, in the Coronary Drug Project (8) and the
Beta-blocker Heart Attack Trial (9), persons who took
placebo medication as directed had a 40% to 50% lower risk
of coronary events compared with those who were nonad-
herent. None of the usual coronary risk factors accounted
for this beneficial effect of adherence. Women who are
classified as “hormone users” in observational studies are, by
definition, adherent.
Use of surrogate outcomes can also give the wrong
answer. For example, encainide and flecainide, two drugs
that clearly suppress ventricular arrhythmia (a surrogate
outcome), increased mortality in trials among persons with
heart failure (10). Multiple positive inotropes, despite im-
proving ejection fraction and other hemodynamic measures
(surrogate outcomes), also increased mortality among per-
sons with heart failure in clinical trials.
Randomized trials are important to define the efficacy and
safety of any intervention. Trials are particularly crucial in
testing the value of estrogen, because we are proposing to
treat healthy, asymptomatic women with a drug that is
known to have important adverse effects, including uterine
bleeding and breast tenderness, and increased risk for
venous thrombosis, gallbladder disease and possibly breast
cancer. To date, the only randomized clinical trial that has
evaluated the effect of postmenopausal hormone therapy on
coronary disease is the Heart and Estrogen/progestin Re-
placement Study (HERS). In this trial, 2,763 postmeno-
pausal women with documented coronary disease and a
uterus were treated with conjugated estrogen plus medroxy-
progesterone acetate or a placebo for an average of four
years. Despite a marked reduction in LDL cholesterol and
increase in HDL cholesterol (good surrogate markers),
there was no overall reduction in risk of coronary events,
coronary bypass surgery, revascularization or hospitalization
for unstable angina (11). Among HERS participants, 60%
had smoked in the past, but only 13% were current
smokers—too few to detect an effect of hormone therapy on
coronary disease rates among smokers.
In summary, there is observational evidence that, among
smokers, postmenopausal hormone therapy reduces risk for
surrogate outcomes associated with coronary disease. This
possible benefit is not seen in premenopausal women using
contraceptive estrogen, and is not supported by data from a
randomized trial. Given this lack of convincing evidence,
medical professionals should work hard to help postmeno-
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pausal women discontinue smoking, rather than treating
them with estrogen—an unproved and potentially danger-
ous intervention.
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